Skip to main content

Table 4 Multivariate analysis of prognostic factors for locally advanced NPC

From: Prognostic value and predictive threshold of tumor volume for patients with locally advanced nasopharyngeal carcinoma receiving intensity-modulated radiotherapy

Endpoint

Variable

Regression coefficient

Standard error

P value

HR

95% CI

OS

Age (<50 vs. ≥50 years)

0.793

0.251

0.002

2.209

1.350–3.616

T category (T3 vs. T4)

0.134

0.452

0.766

1.144

0.472–2.775

N category (N0 vs. N1 vs. N2 vs. N3)

0.364

0.133

0.006

1.439

1.108–1.868

Sex (male vs. female)

−0.168

0.278

0.547

0.845

0.490–1.459

Pathologic type (WHO I vs. II–III)

0.415

0.473

0.380

1.515

0.599–3.830

Chemotherapy (yes vs. no)

−0.409

0.484

0.398

0.664

0.257–1.716

Radiation dose (<73.92 vs. ≥73.92 Gy)

−0.189

0.437

0.666

0.828

0.352–1.950

GTV-P (≤46.4 vs. >46.4 mL)

0.901

0.261

0.001

2.463

1.478–4.104

LRFS

Age (<50 vs. ≥50 years)

1.768

0.578

0.002

5.857

1.887–18.186

T category (T3 vs. T4)

−0.151

0.801

0.851

0.86

0.179–4.133

N category (N0 vs. N1 vs. N2 vs. N3)

−0.108

0.249

0.663

0.897

0.551–1.462

Sex (male vs. female)

0.150

0.571

0.793

1.162

0.379–3.557

Pathologic type (WHO I vs. II-III)

0.355

0.765

0.643

1.426

0.318–6.391

Chemotherapy (yes vs. no)

−0.369

0.776

0.634

0.691

0.151–3.165

Radiation dose (<73.92 vs. ≥73.92 Gy)

−0.659

1.038

0.525

0.517

0.068–3.956

GTV-P (≤46.4 vs. >46.4 mL)

1.029

0.520

0.048

2.798

1.010–7.746

DMFS

Age (< 50 vs. ≥ 50 years)

0.252

0.281

0.370

1.287

0.741–2.234

T category (T3 vs. T4)

0.559

0.543

0.303

1.749

0.604–5.068

N category (N0 vs. N1 vs. N2 vs. N3)

0.418

0.147

0.005

1.519

1.138–2.027

Sex (male vs. female)

−0.132

0.303

0.664

0.877

0.485–1.586

Pathologic type (WHO I vs. II-III)

0.255

0.525

0.627

1.291

0.461–3.611

Chemotherapy (yes vs. no)

−0.178

0.613

0.771

0.837

0.252–2.780

Radiation dose (<73.92 vs. ≥73.92 Gy)

−0.024

0.440

0.956

0.976

0.412–2.313

GTV-P (≤46.4 vs. >46.4 mL)

0.963

0.280

0.001

2.620

1.514–4.534

DFS

Age (<50 vs. ≥50 years)

0.535

0.225

0.018

1.708

1.098–2.656

T category (T3 vs. T4)

0.376

0.415

0.365

1.457

0.646–3.286

N category (N0 vs. N1 vs. N2 vs. N3)

0.287

0.118

0.015

1.333

1.057–1.680

Sex (male vs. female)

−0.114

0.251

0.649

0.892

0.545–1.459

Pathological type (WHO I vs. II-III)

0.423

0.401

0.292

1.526

0.695–3.350

Chemotherapy (yes vs. no)

−0.337

0.441

0.445

0.714

0.301–1.694

Radiation dose (< 73.92 vs. ≥ 73.92 Gy)

−0.105

0.379

0.781

0.900

0.428–1.891

GTV-P (≤ 46.4 vs. > 46.4 mL)

0.848

0.230

<0.001

2.335

1.487–3.667

  1. HR hazard ratio, CI confidence interval, OS overall survival, LRFS local relapse-free survival, DMFS distant metastasis-free survival, DFS disease-free survival
  2. P values were calculated using an adjusted Cox proportional hazards model
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us